Endonovo Therapeutics, Inc. Overview
Pro stress-test →Endonovo Therapeutics is a biotechnology company engaged in the development, manufacture, and distribution of non-invasive Electroceutical medical devices for regenerative medicine. The company's Immunotronics platform is a non-invasive bioelectronic device for treating vital organ failure through reduction of inflammation, while Cytotronics uses Time-Varying Electromagnetic Fields for tissue engineering and cell therapies.
Strategic Profile
Pro stress-test →Endonovo is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The company's primary product offering is SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. The company operates as a microcap biotech with extremely limited resources and liquidity.
Competitive Landscape
Pro stress-test →Endonovo operates in the bioelectronic regenerative medicine space, competing indirectly with broader regenerative medicine companies and electroceutical device developers. The company faces significant competitive disadvantages due to its minimal capitalization, staffing constraints, and lack of clinical validation relative to better-funded biotech players in wound care, tissue engineering, and organ regeneration.
Industry Context
Endonovo Therapeutics, Inc. operates in Bioelectronic regenerative medicine devices.
Key facts
Headquarters: Woodland Hills, US · Employees: 1 · Revenue: $16K (trailing twelve months) · Market cap: $31K-$181K (as of June 2026)